MarketCapExport financials
AgeX Therapeutics (AGE)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
AgeX Therapeutics Income Statement 2025-2011 | AGE
Brief overview of revenue and earnings at AgeX Therapeutics
The comparison covers a five-year financial horizon. According to figures from AgeX Therapeutics, revenue changed from $1.9 million to $130 thousand over five years. The total change was −93%, with a CAGR of approximately −41.3%. The negative rate indicates weakening core operations.
EBITDA was −$9.4 million at the beginning and −$23.9 million at the end of the period (−154.5%). The operating result developed less favorably than sales. EBITDA margin was −503.3% at the start and −18401.5% at the end. The business retained less EBITDA from each unit of revenue.
Across the five years, the net result shifted from $2 million to −$19.2 million. The move from profit to loss indicates a material deterioration in final efficiency.
What the figures show
Signs of deterioration dominate the five-year picture. The main areas of concern are pressure on operating profitability, a weaker final result and a narrow EBITDA buffer. Further direction will depend on top-line growth, operating profitability, and net income.
Annual Income Statement AgeX Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | - | 29.1 M | 679 | 30.4 M | 65.5 M | 52.6 M | 137 M | - | 132 M | - | - | - | - | - |
Shares |
10.2 M | 7.36 M | 2.24 M | 1.08 K | 37.9 M | 37.7 M | 37.3 M | 34.9 M | - | 35.8 M | - | - | - | - | - |
Historical Prices |
- | - | 13 | 0.63 | 0.803 | 1.74 | 1.37 | 3.87 | - | - | - | - | - | - | - |
Net Income |
-19.2 M | -11.1 M | 5.27 M | -10.5 M | -8.68 M | 2 M | -12.2 M | -7.5 M | -6.58 M | - | - | - | - | - | - |
Revenue |
130 K | 56 K | 3.15 M | 34 K | 144 K | 1.87 M | 1.73 M | 1.4 M | 1.4 M | - | - | - | - | - | - |
Cost of Revenue |
- | - | 40 K | 13 K | 19 K | 26 K | 244 K | 364 K | 168 K | - | - | - | - | - | - |
Gross Profit |
- | - | 102 K | 21 K | 125 K | 1.71 M | 1.48 M | 1.03 M | 1.24 M | - | - | - | - | - | - |
Operating Income |
-24 M | -17 M | -3.13 M | -6.98 M | -7.93 M | -10.1 M | -12.6 M | -11.2 M | -6.66 M | - | - | - | - | - | - |
Interest Expense |
51 K | 228 K | 4.9 M | 3.34 M | 1.1 M | 105 K | 294 K | - | - | - | - | - | - | - | - |
EBITDA |
-23.9 M | -16.9 M | -3.04 M | -6.84 M | -7.8 M | -9.4 M | -11.6 M | -10.7 M | -7.74 M | - | - | - | - | - | - |
Operating Expenses |
24.2 M | 17.1 M | 6.28 M | 7 M | 8.16 M | 12.4 M | 14 M | 12.3 M | 9.65 M | - | - | - | - | - | - |
General and Administrative Expenses |
11 M | 9.62 M | 3.89 M | 5.97 M | 6.71 M | 7.4 M | 8.14 M | 5.65 M | 3.87 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement AgeX Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
10 M | 12 M | - | 10.3 M | 10 M | 9.76 M | 9.42 M | 8.85 M | 8.51 M | 2.79 M | 2.41 M | 2.19 M | 2.17 K | 2.17 M | 37.9 M | 37.9 K | 37.9 K | 37.9 M | 37.9 M | 37.9 M | 37.9 K | 37.7 M | 37.7 M | 37.7 M | 37.7 M | 37.7 M | 37.6 M | 37.6 K | 37.6 M | 36.1 K | 35.8 M | 35.8 K | 34.2 M | 33.8 M | 33.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-6.56 M | -6.9 M | - | -4.58 M | -6.45 M | -4.81 M | - | 1.41 M | 5.2 M | -15 M | - | 1.75 M | 808 K | 1.66 M | - | -2.44 M | -2.62 M | -2.71 M | - | -1.96 M | -2.47 M | -2.09 M | - | -2.54 M | 2 M | -3.19 M | - | -3.22 M | -3.09 M | -3.13 M | - | -2.15 M | -1.93 M | -235 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
130 K | - | - | - | 130 K | - | - | 14 K | 51 K | 5 K | - | 29 K | 7 K | 30 K | - | 9 K | 12 K | 5 K | - | 24 K | 37 K | 56 K | - | 69 K | 45 K | 89 K | - | 411 K | 380 K | 388 K | - | 380 K | 464 K | 239 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | - | 33 K | 5 K | 1 K | - | 5 K | 6 K | 1 K | - | 2 K | 13 K | 3 K | - | 17 K | 3 K | 1 K | - | 49 K | 53 K | 63 K | - | -4 K | 79 K | 109 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | 34 K | 4 K | 9 K | - | 4 K | 6 K | 4 K | - | 22 K | 24 K | 53 K | - | 52 K | 42 K | 88 K | - | 362 K | 327 K | 325 K | - | 384 K | 385 K | 130 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-5.56 M | - | - | -6.39 M | -5.56 M | -5.86 M | - | -5.31 M | -3.87 M | -2.32 M | - | -1.46 M | -945 K | -962 K | - | -1.55 M | -1.59 M | -2.05 M | - | -1.67 M | -2.2 M | -2.19 M | - | -2.4 M | -2.37 M | -3.01 M | - | -3.28 M | -3.44 M | -3.12 M | - | -2.2 M | -2.13 M | -3.55 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
68 K | 60 K | - | 35 K | 68 K | - | - | 42 K | 56 K | 99 K | - | 105 K | 792 K | 86 K | - | 923 K | 863 K | 571 K | - | 285 K | 4 K | 437 K | - | -12 K | 1 K | 5 K | - | 48 K | 257 K | -28 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-5.56 M | - | - | - | - | -5.84 M | - | - | -3.84 M | -2.3 M | - | -1.43 M | -927 K | -949 K | - | -1.52 M | -1.56 M | -2.02 M | - | -1.58 M | -2.17 M | -1.96 M | - | -2.17 M | -2.14 M | -2.78 M | - | -3.16 M | -3.33 M | -3.11 M | - | -2.18 M | -2.12 M | -3.54 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
5.7 M | 6.28 M | - | 6.39 M | 5.7 M | 5.86 M | - | 5.33 M | 3.92 M | 2.33 M | - | 1.49 M | 952 K | 992 K | - | 1.55 M | 1.6 M | 2.06 M | - | 1.7 M | 2.23 M | 2.35 M | - | 2.45 M | 2.41 M | 3.1 M | - | 3.64 M | 3.77 M | -3.45 M | - | -2.59 M | 2.52 M | 3.68 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
2.54 M | 3.08 M | - | 2.74 M | 2.54 M | 2.91 M | - | 2.91 M | 2.32 M | 1.22 M | - | 889 K | 473 K | 593 K | - | 1.39 M | 1.34 M | 1.66 M | - | 1.42 M | 1.75 M | 2.02 M | - | 1.8 M | 1.48 M | 1.88 M | - | 2.19 M | 2.12 M | 2.11 M | - | 1.25 M | 1.14 M | 1.29 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company AgeX Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
Niderland
Danmark
Britain
China
Israel
